NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a cash flow conversion efficiency ratio of -0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.77 Million) by net assets ($728.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NAMS net asset quality score to measure how much of total assets are equity-financed.
NewAmsterdam Pharma Company N.V. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NAMS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NewAmsterdam Pharma Company N.V. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
-0.168x |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
-0.003x |
|
Standex International Corporation
NYSE:SXI
|
0.028x |
|
TOMRA SYSTEMS ADR/1 NK 1
F:TMR0
|
0.094x |
|
China Communications Construction Company Limited
F:CYY
|
-0.051x |
|
Simmons First National Corporation
NASDAQ:SFNC
|
0.012x |
|
Huaneng Power International Inc
F:HUP1
|
0.034x |
|
HEXPOL AB (publ)
ST:HPOL-B
|
0.066x |
Annual Cash Flow Conversion Efficiency for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see NAMS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $757.50 Million | $-158.56 Million | -0.209x | +57.25% |
| 2023-12-31 | $288.39 Million | $-141.22 Million | -0.490x | -2074.60% |
| 2022-12-31 | $430.07 Million | $10.66 Million | 0.025x | +104.76% |
| 2021-12-31 | $56.63 Million | $-29.51 Million | -0.521x | -804.70% |
| 2020-12-31 | $127.46 Million | $-7.34 Million | -0.058x | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more